UPDATE: GW’s Epidiolex on April 19 received a unanimous recommendation from the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Association. The following article has been updated to reflect that decision. This is a make-or-break spring for GW Pharmaceuticals and its billion-dollar investment in a cannabidiol-based drug. The London-based firm aims to develop the first FDA-approved medicine from plant-derived cannabis compounds. The U.S.
Similar Stories to Gw Pharmaceuticals’ Ceo Talks Epidiolex, Future Of Cannabidiol Medicine on Bing News
Alicia Wallace, Denver Post: Business
Thu, 04/19/2018 - 8:12pm
Topics: update gw s epidiolex april peripheral central nervous system drugs advisory committee association the london-based the u.s food drug administration june the cannabist gw pharmaceuticals ceo justin gover in thursday s epidiolex s fda-approved cbd we read gw epidiolex drug u.s food gw pharmaceuticals fda fda-approved epidiolex cbd future cannabidiol medicine received positive unanimous recommendation
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more